Charles Schwab Investment Management Inc. Sells 143,671 Shares of Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Aurinia Pharmaceuticals by 21.6% in the first quarter, now owning approximately 0.38% of the company valued at $4.19 million.
• Deutsche Bank AG increased its stake by 54.8% in the fourth quarter, and other institutional investors have also modified their holdings significantly.
• Aurinia Pharmaceuticals reported $0.16 EPS for the quarter, missing estimates, but had revenue of $70.01 million which was above expectations.

Charles Schwab Investment Management Inc. lessened its stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 21.6% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 521,416 shares of the biotechnology company's stock after selling 143,671 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.38% of Aurinia Pharmaceuticals worth $4,192,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $27,000. Tower Research Capital LLC TRC lifted its holdings in shares of Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after buying an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $31,000. GAMMA Investing LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after buying an additional 1,744 shares in the last quarter. Finally, USA Financial Formulas purchased a new position in shares of Aurinia Pharmaceuticals in the first quarter worth $50,000. Hedge funds and other institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Price Performance

Aurinia Pharmaceuticals stock traded down $0.09 during mid-day trading on Monday, reaching $11.99. 805,789 shares of the company's stock traded hands, compared to its average volume of 2,243,871. The company has a market cap of $1.58 billion, a price-to-earnings ratio of 27.88 and a beta of 1.26. The stock has a 50 day moving average of $9.89 and a two-hundred day moving average of $8.68. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a 12-month low of $6.42 and a 12-month high of $12.53.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million for the quarter, compared to analysts' expectations of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang purchased 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 5th. The shares were bought at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the completion of the purchase, the director directly owned 11,329,500 shares in the company, valued at $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have acquired a total of 1,300,000 shares of company stock worth $13,590,000 over the last quarter. 12.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently commented on AUPH. HC Wainwright reissued a "buy" rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Royal Bank Of Canada boosted their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $12.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.